-
Today’s Stocks: ProQR Therapeutics N.V. (NASDAQ:PRQR), Frontier Communications Corporation (NASDAQ:FTR), National American University Holdings (NASDAQ:NAUH), AstraZeneca PLC (NYSE:AZN), General Motors (NYSE:GM)
On Tuesday shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at $19.61. ProQR Therapeutics N.V. (NASDAQ:PRQR), announced that the Annual General Meeting of Shareholders will be held on Wednesday, June 10, 2015 at 16:00 CET, at Naturalis Biodiversity Center at Darwinweg 2, 2333 CR Leiden, the Netherlands. Frontier Communications Corporation (NASDAQ:FTR) in last trading activity fell…
-
Notable Ups And Down: ProQR Therapeutics N.V. (NASDAQ:PRQR), Tuniu Corporation (NASDAQ:TOUR), CME Group Inc. (NASDAQ:CME), Marsh & McLennan (NYSE:MMC), News Corporation (NASDAQ:NWSA)
On Feb. 26, ProQR Therapeutics N.V. (NASDAQ:PRQR), announced results for the fourth quarter and full year 2014. Net cash generated by financing activities during the year ended December 31, 2014 was €119.9 million. This includes the net proceeds from our IPO in the third quarter of 2014 and the net proceeds from the private placement…
-
Stocks on the move: ProQR Therapeutics N.V. (NASDAQ:PRQR), Newmont Mining (NYSE:NEM), Cisco Systems (NASDAQ:CSCO), Alcatel Lucent (NYSE:ALU), International Business Machines (NYSE:IBM)
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced results for the fourth quarter and full year 2014. Net loss for the three months ended December 31, 2014 was €2.0 million, or €0.09 per share, compared to €1.6 million, or €0.27 per share for the same period in 2013. On Tuesday shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at…
-
Investors Are Eying: Zoetis Inc. (NYSE:ZTS), ProQR Therapeutics N.V. (NASDAQ:PRQR), Athersys (NASDAQ:ATHX), Marriott Vacations Worldwide Corp. (NYSE:VAC), Qualys (NASDAQ:QLYS)
Zoetis Inc. (NYSE:ZTS) said its fourth-quarter earnings rose 20% on stronger revenue, though the animal-health company was the latest to have currency fluctuations weigh on growth. For 2015, the company lowered its revenue outlook slightly to $4.8 billion to $4.9 billion, from its previous estimate for $4.85 billion to $4.95 billion and affirmed its per-share…
-
Stay on: ProQR Therapeutics N.V. (NASDAQ:PRQR), CSG Systems International Inc. (NASDAQ:CSGS), Grupo Financiero Santander Mexico (NYSE:BSMX), Old Republic International (NYSE:ORI), Alcatel-Lucent (NYSE:ALU)
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 2:40 pm EST in New York, NY, USA. On Thursday shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at $17.40. CSG Systems International Inc.…
-
5 Stocks in Dramatic Moves: Tandem Diabetes Care (NASDAQ:TNDM), ProQR Therapeutics (NASDAQ:PRQR), Horace Mann Educators (NYSE:HMN), Hillenbrand (NYSE:HI), Republic Services (NYSE:RSG)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a research note issued on Monday. On Wednesday shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) closed at $12.38. Company’s EPS growth for next 5 years is recorded as 15.94%. ProQR Therapeutics N.V. (NASDAQ:PRQR) announced that…
-
Investors Are Eying: Receptos (NASDAQ:RCPT), ProQR Therapeutics N.V. (NASDAQ:PRQR), Sapient Corp. (NASDAQ:SAPE), Guidance Software (NASDAQ:GUID), Delta Air Lines (NYSE:DAL)
On December 9, Receptos Inc (NASDAQ:RCPT), 2 analysts have set the short term price target of Receptos Inc (NASDAQ:RCPT) at $173. The standard deviation of short term price target has been estimated at $18.39, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 186 and…
-
Biotech Gainers: Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), CorMedix (NYSEMKT:CRMD), Akebia Therapeutics (NASDAQ:AKBA), Vital Therapies (NASDAQ:VTL), ProQR Therapeutics N.V. (NASDAQ:PRQR)
Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) on Nov. 11 announced it has received a $1.1 million refund of the previously paid Prescription Drug User Fee Act (PDUFA) filing fee related to the granting of orphan drug status of Lymphoseek® (technetium Tc 99m tilmanocept) injection in head and neck cancers. Lymphoseek was granted Orphan Drug Designation by the…
-
Don’t Miss: ProQR Therapeutics N.V. (NASDAQ:PRQR), Boston Scientific Corporation (NYSE:BSX), Kemper Corporation (NYSE:KMPR), ARMOUR Residential REIT (NYSE:ARR), The Spectranetics Corporation (NASDAQ:SPNC)
HC Waintwright initiated coverage on shares of ProQR Therapeutics NV (NASDAQ:PRQR) in a research report sent to investors on Monday morning. The firm issued a buy rating and a $40.00 price target on the stock. ProQR Therapeutics N.V. (NASDAQ:PRQR) in last trading activity advanced 3.14% to close at $12.14. Company weekly performance is 2.62%. ProQR…